Adaptive Biotechnologies Corp vs Global X Robo Global Robotics & Automation ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Global X Robo Global Robotics & Automation ETF trades at $84.48. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | ROBO | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $25.45 | $90.34 |
52-Week Low | $12.30 | $62.34 |
Enterprise Value | $4.10B | — |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
ROBO trades at $84.50, up 1.25% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent news highlights robotics stocks rallying, with thematic ETF interest growing in AI and automation. The stock shows strong momentum but lacks disclosed financial ratios, requiring deeper fundamental verification.
Outlook is cautiously optimistic due to sector tailwinds from AI infrastructure growth, but risks include cyclical exposure and high valuations. Investors should assess upcoming earnings for profitability metrics, as current data gaps limit fundamental clarity amid positive market sentiment.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →